Welcome to our dedicated page for Viatris Ord Shs SEC filings (Ticker: VTRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viatris Inc. (Nasdaq: VTRS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand how Viatris reports its financial performance, governance decisions and key corporate events as a global healthcare company that bridges generics and brands.
Viatris regularly files current reports on Form 8‑K to announce material events such as quarterly financial results, changes to bylaws, board appointments and other significant corporate actions. For example, the company has used Form 8‑K to report results for periods ended June 30 and September 30, 2025, and to disclose amendments to its bylaws related to proxy access and annual meeting timing. These filings often reference accompanying press releases that provide additional detail.
The company’s proxy statement on Schedule 14A (DEF 14A) offers insight into governance, board composition, executive compensation and strategic priorities. In its definitive proxy statement, Viatris discusses its enterprise-wide strategic review, capital return plans, pipeline progress and long-term shift toward a greater share of innovative brands, giving shareholders context for voting decisions and for evaluating management’s plans.
On this page, users can also monitor other SEC forms that may appear over time, such as annual and quarterly reports or any insider transaction reports on Form 4, as they become available. Stock Titan enhances these filings with AI-powered summaries that highlight key points, explain technical language and help readers quickly identify topics such as revenue trends, strategic initiatives, bylaw changes and risk factors relevant to Viatris’ pharmaceutical preparation manufacturing business.
Filings are updated as they are released through EDGAR, allowing investors, analysts and other stakeholders to follow how Viatris communicates its financial condition, governance framework and strategic evolution through official regulatory channels.
Viatris Inc. (VTRS) reported Q3 2025 results with total revenues of
Year-to-date, results reflect significant non-cash charges: a goodwill impairment of
Viatris Inc. furnished an update on its latest results. The company issued a press release reporting financial results for the period ended September 30, 2025, and furnished it under Item 2.02 of an 8‑K. The information is provided as furnished, not filed, and is included as Exhibit 99.1.
The company also announced a conference call and live webcast today at 8:30 a.m. ET to review third-quarter 2025 results. Additional exhibit materials include the cover page Inline XBRL tags (Exhibit 104).
Viatris Inc. amended and restated its bylaws effective October 24, 2025, updating proxy access timing rules when the annual meeting date shifts. The company set its 2026 annual meeting for May 15, 2026.
Shareholder deadlines: Rule 14a-8 proposals are due by November 24, 2025. Proxy access nominations (up to the greater of two nominees or 20% of the Board) must be received between December 16, 2025 and January 15, 2026. Advance notice for other director nominations or business must be delivered between January 15, 2026 and February 14, 2026. Universal proxy notices under Rule 14a-19 are due by March 16, 2026.
Viatris (VTRS) filed its 2025 proxy statement calling a December 5, 2025 annual meeting in Hollywood, FL. Shareholders will vote to elect 13 directors, approve on an advisory basis 2024 compensation for named executive officers, and ratify Deloitte & Touche LLP as auditor for fiscal 2025. The record date is October 10, 2025.
The Board highlights governance changes and refreshment: an independent Chair, a planned reduction of the Board to 13 seats after the meeting, and 12 of 13 nominees deemed independent. Seven new directors have been added since December 2022. Following shareholder feedback on 2024 Say‑on‑Pay, the Board ended the Chairman Emeritus consulting arrangement effective June 30, 2025 and adjusted pay design, including cutting 2024 annual incentive funding to 140% from the formula outcome of 163.92%, raising the 2025 maximum Adjusted EBITDA hurdle to 110% of target, reducing the regulatory submissions weight to 10%, adding a 10% personal objective, and tightening share ownership rules.
Operationally, the company cites returning more than $630 million to shareholders in 1H 2025, five positive Phase 3 readouts, and the first global approval for sotagliflozin.
Viatris Inc. (VTRS) submitted a Form 144 reporting a proposed sale of 7,032 common shares with an aggregate market value of $72,044.59. The filing lists 1,165,872,127 shares outstanding and an approximate sale date of 09/11/2025 on NASDAQ. The securities were acquired on 03/04/2025 as restricted stock units that vested and are described as a compensatory payment. The broker/contact block lists an address for Viatris Inc. in Canonsburg, PA. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.
Insider grant reported: Viatris Inc. director and officer Andrew Enrietti received a grant of 75,401 restricted stock units (RSUs) on 08/15/2025. Each RSU represents the right to one share of Viatris common stock. The RSUs vest in three annual tranches: 25,134 shares vest on 08/15/2026, 25,133 on 08/15/2027, and 25,134 on 08/15/2028. Following the grant, Enrietti beneficially owns 75,401 shares reported as direct ownership. The Form 4 was signed by power of attorney on 08/19/2025 and lists Enrietti's title as Chief Administrative and Transformation Officer.
Viatris Inc. (VTRS) Form 3 reports that Andrew Enrietti, identified as an officer and director-level executive (Chief Administrative and Transformation Officer), beneficially owns 130,000 shares of common stock directly and holds multiple employee equity awards. The filing lists vested stock options exercisable between 2026 and 2030 covering 11,697 options and several restricted stock unit grants and dividend equivalent units totaling 99,237 underlying shares scheduled to vest on specified dates between 2026 and 2028.
Scott A. Smith, who serves as both Chief Executive Officer and a director of Viatris Inc. (VTRS), acquired 22,000 shares of the company’s common stock on 08/12/2025 at a weighted average price of $9.9882 per share. After the purchase, the reporting person directly beneficially owned 314,807 shares.
The filing notes the acquisition price represents a weighted average of purchases in a range from $9.68 to $10.12; the reporting person offered to provide detailed per-price quantities on request. This Form 4 discloses an insider purchase by the CEO, showing an increase in his direct holdings without any derivative transactions reported.
Viatris director David S. Simmons reported the acquisition of 22,820 restricted stock units (RSUs) with a transaction date of 08/11/2025. Each RSU represents the right to receive one share of Viatris common stock at a $0 conversion price, and the award is scheduled to vest on March 6, 2026, at which point the RSUs convert into common shares.
The Form 4 shows this as an insider equity award reported by a single reporting person and executed under a power of attorney. The filing documents an equity grant/vesting schedule rather than a sale or cash purchase.
FAQ
What is the current stock price of Viatris Ord Shs (VTRS)?
What is the market cap of Viatris Ord Shs (VTRS)?
